← Human Trials & Peer-Reviewed Studies
Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy
Plain-language guide to PMID 8790198 (1996): single-blind randomized controlled trial study of VIP (Vasoactive Intestinal Peptide) in 10 patients.
Key Facts
- PMID
- 8790198
- Journal
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Raderer M et al. (11 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of VIP (Vasoactive Intestinal Peptide), published as a randomized controlled trial.
Several other receptors and antigens including the TAG-72 protein have also been implemented for in vivo localization purposes.
In this study, the researchers have compared the in vitro and in vivo binding of 123I-VIP and of the 111In-labeled monoclonal antibody (MAb) directed against TAG-72 (OncoScint; 111In-CR-103) in patients with intestinal adenocarcinomas in a single-blinded, prospectively randomized trial.
Who Took Part
According to the abstract, 10 patients were involved.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized and single-blind study.
The patients were allocated by chance, so the VIP (Vasoactive Intestinal Peptide) group and the comparison group should start out alike.
In this single-blind VIP (Vasoactive Intestinal Peptide) study one party knew the assignments and the other did not.
What Was Measured
In this study, the researchers have compared the in vitro and in vivo binding of 123I-VIP and of the 111In-labeled monoclonal antibody (MAb) directed against TAG-72 (OncoScint; 111In-CR-103) in patients with intestinal adenocarcinomas in a single-blinded, prospectively randomized trial.
The subject headings attached to it are Adenocarcinoma, Antibodies, Monoclonal, Gastrointestinal Neoplasms, Indium Radioisotopes, Iodine Radioisotopes, Liver Neoplasms and Oligopeptides.
What This Means in Plain Language
The paper is a randomized and single-blind study of VIP (Vasoactive Intestinal Peptide) in 10 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1996 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.